CoChat
Sign Up
Cited by 160Epilepsy research and treatmentPharmacological Effects and Toxicity StudiesGenetics and Neurodevelopmental Disorders

Safety and efficacy of ganaxolone in patients with CDKL5 deficiency disorder: results from the double-blind phase of a randomised, placebo-controlled, phase 3 trial

Open access
Knight, Elia M Pestana, Amin, Sam, Bahi-Buisson, Nadia, Benke, Tim A, Cross, J Helen, Demarest, Scott T, Olson, Heather E, Specchio, Nicola +37 more·2022·The Lancet Neurology
DOI 10.1016/s1474-4422(22)00077-1
Open this paper in CoChat — free accountOpen PDF

Abstract

Background CDKL5 deficiency disorder (CDD) is a rare, X-linked, developmental and epileptic encephalopathy characterised by severe global developmental impairment and seizures that can begin in the first few months after birth and are often treatment refractory. Ganaxolone, an investigational neuroactive steroid, reduced seizure frequency in an open-label, phase 2 trial that included patients with CDD. We aimed to further assess the efficacy and safety of ganaxolone in patients with CDD-associated refractory epilepsy.Methods In the double-blind phase of this randomised, placebo-controlled, phase 3 trial, done at 39 outpatient clinics in eight countries (Australia, France, Israel, Italy, Poland, Russia, the UK, and the USA), patients were eligible if they were aged 2-21 years with a pathogenic or probably pathogenic CDKL5 variant and at least 16 major motor seizures (defined as bilateral tonic, generalised tonic-clonic, bilateral clonic, atonic, or focal to bilateral tonic-clonic) per 28 days in each 4-week period of an 8-week historical period. After a 6-week prospective baseline period, patients were randomly assigned (1:1) via an interactive web response system to receive either enteral adjunctive ganaxolone or matching enteral adjunctive placebo (maximum dose 63 mg/kg per day for patients weighing ≤28 kg or 1800 mg/day for patients weighing >28 kg) for 17 weeks. Patients, caregivers, investigators (including those analysing data), trial staff, and the sponsor (other than the investigational product manager) were masked to treatment allocation. The primary efficacy endpoint was percentage change in median 28-day major motor seizure frequency from the baseline period to the 17-week double-blind phase and was analysed (using a Wilcoxon-rank sum test) in all patients who received at least one dose of trial treatment and for whom baseline data were available. Safety (compared descriptively across groups) was analysed in all patients who received at least one dose of trial treatment. This study is registered with ClinicalTrials.gov, NCT03572933, and the open-label extension phase is ongoing.Findings Between June 25, 2018, and July 2, 2020, 114 patients were screened for eligibility, of whom 101 (median age 6 years [IQR 3 to 10]) were randomly assigned to receive either ganaxolone (n=50) or placebo (n=51). All patients received at least one dose of a study drug, but seizure frequency for one patient in the ganaxolone group was not recorded at baseline and so the primary endpoint was analysed in a population of 100 patients. There was a median percentage change in 28-day major motor seizure frequency of -30·7% (IQR -49·5 to -1·9) in the ganaxolone group and of -6·9% (-24·1 to 39·7) in the placebo group (p=0·0036). The Hodges-Lehmann estimate of median difference in responses to ganaxolone versus placebo was -27·1% (95% CI -47·9 to - 9·6). Treatment-emergent adverse events occurred in 43 (86%) of 50 patients in the ganaxolone group and in 45 (88%) of 51 patients in the placebo group. Somnolence, pyrexia, and upper respiratory tract infections occurred in at least 10% of patients in the ganaxolone group and more frequently than in the placebo group. Serious adverse events occurred in six (12%) patients in the ganaxolone group and in five (10%) patients in the placebo group. Two (4%) patients in the ganaxolone group and four (8%) patients in the placebo group discontinued the trial. There were no deaths in the double-blind phase.Interpretation Ganaxolone significantly reduced the frequency of CDD-associated seizures compared with placebo and was generally well tolerated. Results from what is, to our knowledge, the first controlled trial in CDD suggest a potential treatment benefit for ganaxolone. Long-term treatment is being assessed in the ongoing open-label extension phase of this trial.Funding Marinus Pharmaceuticals.

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1016/s1474-4422(22)00077-1

Cites

36 of 36 references verified0 citation errors · 0 not checkable

Statistics

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

  • A RCT in CDKL5 deficiency disorder found a median percentage change in 28-day major motor seizure frequency of -30.7% with ganaxolone, compared with -6.9% for placebo.

    “A RCT in CDKL5 deficiency disorder found a median percentage change in 28-day major motor seizure frequency of -30.7% with ganaxolone, compared with -6•9% for placebo.”

    From Developmental and epileptic encephalopathies (2024) · cites this paper as [192]

  • Treatment-emergent adverse events occurred in 43 of 50 (86%) patients in the ganaxolone group and in 45 of 51 (88%) patients in the placebo group.

    “Treatment-emergent adverse events occurred in 43 of 50 (86%) patients in the ganaxolone group and in 45 of 51 (88%) patients in the placebo group 192 .”

    From Developmental and epileptic encephalopathies (2024) · cites this paper as [192]

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Cites

Flagged first, then by citations

1 of the 37 references couldn’t be matched to a known paper.

Research works printed but not linked: 1

  1. Carter RB, Wood PL, Wieland S, et al. Characterization of the anticonvulsant properties of ganaxolone (CCD 1042; 3alpha-hydroxy-3beta-methyl-5alpha-pregnan-20-one), a selective, high- affinity, steroid modulator of the gamma-aminobutyric acid(A) receptor. J Pharmacol Exp Ther 1997; 280: 1284-95.

Cited by

Sorted by citations

Related

Authors
Knight, E. M. P., Amin, S., Bahi-Buisson, N., Benke, T. A., Cross, J. H., Demarest, S. T., Olson, H. E., Specchio, N., Fleming, T. R., Aimetti, A. A., Gasior, M., Devinsky, O., Belousova, E., Belyaev, O., Ben-Zeev, B., Brunklaus, A., Ciliberto, M. A., Darra, F., Davis, R., De Giorgis, V., Doronina, O., Fahey, M., Guerrini, R., Heydemann, P., Khaletskaya, O., Lisewski, P., Marsh, E. D., Moosa, A. N., Perry, S., Philip, S., Rajaraman, R. R., Renfroe, B., Saneto, R. P., Scheffer, I. E., Sogawa, Y., Suter, B., Sweney, M. T., Tarquinio, D., Veggiotti, P., Wallace, G., Weisenberg, J., Wilfong, A., Wirrell, E. C., Zafar, M., & Zolnowska, M.
Affiliations
  • Cleveland Clinic (US)
  • University Hospitals Bristol and Weston NHS Foundation Trust (GB)
  • Children's Hospital Colorado (US)
  • University College London (GB)
  • Boston Children's Hospital (US)
  • Bambino Gesù Children's Hospital (IT)
  • University of Washington (US)
  • Marinus Pharmaceuticals (United States) (US)
  • NYU Langone Health (US)
Corresponding author
Knight, Elia M Pestana
ORCID
Venue
The Lancet Neurology
Publisher
Elsevier BV
Published
2022-05
Volume
21
Issue
5
Pages
417-427
ISSN
1474-4422 (ISSN-L)
DOI
10.1016/s1474-4422(22)00077-1
OpenAlex
W4224128253
Cited by
160
References
37
Citations by year
2026: 22 · 2025: 40 · 2024: 43 · 2023: 39 · 2022: 16
FWCI
22.46
Type
journal article
Language
en
Update notices
erratum (2022-07-01)
Open access
Licence
Locations
  • The Lancet Neurology (publishedVersion)
  • PubMed (publishedVersion)
  • UCL Discovery (University College London) (submittedVersion)
  • Florence Research (University of Florence) (submittedVersion)
Funders
Marinus Pharmaceuticals
Topics
  • Health Sciences › Medicine › Psychiatry and Mental health › Epilepsy research and treatment
  • Health Sciences › Medicine › Pediatrics, Perinatology and Child Health › Pharmacological Effects and Toxicity Studies
  • Life Sciences › Biochemistry, Genetics and Molecular Biology › Genetics › Genetics and Neurodevelopmental Disorders
Keywords
ganaxolone, CDKL5 deficiency disorder, drug-resistant epilepsy, neurosteroids, seizure frequency, adjunctive antiepileptic therapy, developmental and epileptic encephalopathy, drug safety, adverse events, X-linked disorders, children and adolescents, open-label extension, treatment discontinuation
MeSH terms
Epileptic Syndromes, Child, Child, Preschool, Double-Blind Method, Humans, Infant, Pregnanolone, Prospective Studies, Seizures, Spasms, Infantile, Treatment Outcome, Protein Serine-Threonine Kinases

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review